

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19

To be submitted to 'Mechanisms of Aging and Development

Moderate dietary restriction delays the onset of age-associated sarcopenia in *Caenorhabditis elegans* due to reduced myosin UNC-54 degradation.

Sobha Tumbapo¹, Adam Strudwick¹, Jana J. Stastna¹, Simon C. Harvey^{1,2} and Marieke J. Bloemink^{1*}

¹Biomolecular Research Group, School of Human and Life Sciences, Canterbury Christ Church University, Canterbury CT1 1QU, United Kingdom

²Current address: Faculty of Engineering and Science, University of Greenwich, UK

*Corresponding author: marieke.bloemink@canterbury.ac.uk

20 **Abstract**

21 Sarcopenia, a gradual decrease in skeletal muscle mass and strength, is a major
22 component of frailty in the elderly, with age, (lack of) exercise and diet found to be the
23 major risk factors. The nematode *Caenorhabditis elegans* is an important model of
24 sarcopenia. Although many studies describe loss of muscle function in ageing *C.*
25 *elegans*, surprisingly few report on the loss of muscle mass. Here, in order to quantify
26 loss of muscle mass under various dietary restriction (DR) conditions, we used an
27 internal GFP standard to determine levels of the major body wall muscle myosin (UNC-
28 54) in transgenic *unc-54::gfp* worms over their lifespan. Myosin density linearly
29 increased during the first week of adulthood and there was no significant effect of DR. In
30 contrast, an exponential decrease in myosin density was seen during the second week
31 of adulthood, with reduced rates of myosin loss for mild and medium DR compared to
32 control. UNC-54 turnover rates, previously determined using pulse-labelling methods,
33 correspond well with the $t_{1/2}$ value found here for UNC-54-GFP using fluorescence
34 (control $t_{1/2} = 12.0$ days), independently validating our approach. These data indicate
35 that sarcopenia is delayed in worms under mild and medium DR due to a reduced rate
36 of myosin UNC-54 degradation, thereby maintaining protein homeostasis.

37

38

39

40 **Keywords** – Aging; sarcopenia; *C. elegans*; healthspan; myosin UNC-54

41

42

43 **Introduction**

44 One of the key changes associated with ageing is sarcopenia, the gradual loss of skeletal
45 muscle mass and strength, which leads to loss of functional mobility and independence
46 and increasing risk of falls and fractures (Cruz-Jentoft and Sayer, 2019). Multiple factors
47 have been implicated in the development and progression of sarcopenia, such as
48 hormonal changes, loss of neurons and satellite cells, altered proteostasis, inflammation
49 and oxidative stress, but the molecular mechanisms involving sarcopenia remains unclear
50 (Dao et al., 2020; Wiedmer et al., 2021). Currently there is no effective treatment to
51 reverse sarcopenia, although dietary intervention and exercise can slow the rate of muscle
52 loss (Kim et al., 2022; Domingues-Faria et al., 2016; Phu et al., 2015). With a growing
53 ageing population, it is essential to understand the molecular mechanisms behind
54 sarcopenia in order to develop effective therapies and improve healthspan (Han et al.,
55 2018; Kwak and Kwon, 2019).

56

57 The nematode *Caenorhabditis elegans* has proven to be a valuable model for ageing
58 research, because of its short lifespan (18-21 days), genetic tractability and relatively
59 simple physiology (Christian and Benian, 2020; Son et al., 2019). Similar to what is seen
60 for human sarcopenia, ageing *C. elegans* undergo loss of sarcomere integrity and mobility
61 (Park et al., 2017) (Ibáñez-Ventoso et al., 2016). However, quantifying the extend of
62 sarcopenia in *C. elegans* has proven to be problematic, with most studies using visual
63 assessment of myofilament organization, combined with motility assays that rely on
64 manual scoring, which can be subjective (Herndon et al., 2002). One study recently
65 reported an automated approach to analyze sarcopenia in *C. elegans*, using various
66 descriptors of muscle integrity and organization, for example counting of thick filaments,
67 which allows prediction of biological age and health span (Dhondt et al., 2021). Although
68 this automated approach allows morphological staging of sarcopenia based on muscle
69 architecture, it does not report on the rate of muscle loss, one of the key features of
70 sarcopenia.

71 The current study addresses this gap using a molecular approach to quantify sarcopenia
72 and the rate of muscle loss. To validate this method, sarcopenia rates are evaluated in *C.*
73 *elegans* that are known to experience a delay in sarcopenia onset because of dietary
74 restriction (DR) and compared to a control group. Reducing calorie intake by 20-40%, has
75 proven to be effective in extending lifespan and improving health span, attenuating and
76 delaying the onset of sarcopenia in a wide range of organisms, including *C. elegans*
77 (Hwangbo et al., 2020; Xie et al., 2020). Although this type of DR does not prevent the
78 loss of muscle mass, it can slow down the process significantly, as demonstrated in both
79 rats and rhesus monkeys (McKiernan et al., 2004) (Rhoads et al., 2020) respectively. In
80 *C. elegans*, using longevity mutants, Bansal *et al.* demonstrated that lifespan-extending
81 mutations (*daf-2*, *eat-2*, *ife-2* and *clk-1*) also extend the period of frailty with overall
82 reduced mobility, but did not report specific loss of muscle related to sarcopenia (Bansal
83 et al., 2015).

84

85 This study reports in detail the myosin density of *C. elegans* body wall muscle during its
86 entire lifespan to establish the potential effect of various DR regimes on the rate of muscle
87 loss. Instead of a genetic model of DR in *C. elegans* (e. g., *eat-2* mutant worms), our work
88 uses the solid DR method (sDR) and a transgenic *C. elegans* strain (*unc-54::GFP*), to
89 quantify myosin density in *C. elegans* using fluorescence spectroscopy. This strain has
90 one of its myosin heavy chain isoforms (UNC-54) labelled with GFP (Várkuti et al., 2012).
91 The *unc-54* gene codes for the muscle myosin heavy chain B (MHC B), a major
92 component of the body-wall muscle in *C. elegans* and is essential for locomotion and
93 maintaining structural stability in sarcomeres (Várkuti *et al.*, 2012). To our knowledge, this
94 is the first study documenting the detailed rate of the loss of the major muscle myosin
95 isoform UNC54 in *C. elegans*, exposed to different severities of DR (Greer et al., 2007),
96 over the whole course of its lifespan. Our results show that the onset and rate of
97 sarcopenia is delayed in worms under mild and medium DR, compared to the control, with
98 corresponding slower rates of myosin UNC-54 loss for mild/medium DR groups. This

99 suggests that slower myosin UNC-54 turnover rates contribute to the delay in sarcopenia
100 progression seen in these groups.

101

102 **Materials and Methods**

103 *C. elegans strain and Maintenance*


104 Worms expressing UNC-54::GFP were a generous gift from Dr Andras Malnasi-
105 Csizmadia (Eötvös Loránd University, Budapest, Hungary) and were used in all DR
106 assays. This strain was generated by transforming *unc-54(e1092)* mutants with punc-
107 54::UNC-54::GFP by microparticle bombardment and the subsequent selection of
108 homozygous worms from integrated lines (Várkuti et al., 2012). All populations were grown
109 initially on standard nematode growth medium (NGM) at 20°C with *Escherichia coli* OP50
110 as the food source (Stiernagle, 2006). Unless otherwise stated, *E. coli* OP50 cultures used
111 for seeding plates were inoculated from a single bacterial colony in Luria broth (LB) and
112 allowed to grow overnight at 37°C, before seeding on NGM plates. Synchronous
113 populations of worms were generated by treating gravid adult worms with sodium
114 hypochlorite (bleaching) and the eggs were maintained at 20°C without food for 24 hours.
115 After 24 hours, plates with L1 worms were seeded with OP50 and let to develop for three
116 days to adulthood. The adult worms were then transferred to the experimental plates
117 designed for the assay (Stiernagle, 2006).

118

119 *Dietary restriction assays*

120 The solid DR (sDR) method was adapted from Greer *et al.* (2007) and bacterial
121 concentration was estimated using the method described by (Ching and Hsu, 2011) and
122 summarized in Figure S1. Briefly, OP50 bacteria was grown to saturation, overnight at 37
123 °C. The concentration of the overnight bacterial culture was calculated by plating a serial
124 dilution and subsequent counting of colony forming units (cfu). The bacteria stock was
125 then diluted to achieve concentrations of 8×10^{10} (mild DR-mDR), 8×10^8 (medium DR-
126 mdDR) and 8×10^6 (severe DR-sDR) cfu/ml. 100 μ l of these diluted bacterial cultures were

127 seeded on 55mm nutrient growth media (NGM) plates. The NGM plates were modified by
 128 excluding peptone to prevent bacterial growth (Stastna et al., 2015). The *ad libitum*
 129 (control) was 8×10^{10} cfu/ml and 100 μ l of this was seeded on standard NGM plates. 15
 130 adult worms were placed on each plate starting at day 1 of adulthood, with 4 plates per
 131 treatment, giving a total of 60 individuals per treatment. Plates were randomised and blind
 132 coded. Worms were moved to fresh plates every other day to prevent starvation and
 133 maintain the experimental conditions (Greer et al., 2007). 5-fluoro-2'-deoxyuridine (FUdR)
 134 was added on top of the bacterial lawn 24 hours before worms were introduced to the
 135 plates on the first day of adulthood to prevent reproduction (Hosono, *et al.*, 1989). Worms
 136 were transferred off the FUdR-containing plates once reproduction has ceased (7-10
 137 days). A scheme that summarizes the experimental setup and the frequency of the
 138 measurements being taken is included below:



139
 140 Scheme 1: summary of experimental setup and frequency of measurements. Recordings
 141 started of day 1 of adulthood (L4, young adult) and ended when all individuals of a group
 142 had died, typically 3-4 weeks later.

143 *Lifespan assays*

144 All lifespan assays on *C. elegans* were performed at 20°C and started on day 1 of
145 adulthood (L4 stage, young adult), immediately after transfer of the synchronised adult
146 worms to their respective treatment plates. For each lifespan assay, 4 plates with 15 adult
147 worms each were used per treatment, giving a total of 60 individuals per treatment.
148 Lifespan was measured daily until the end of the population's lifespan, typically 3-4 weeks.
149 by counting the number of dead and alive worms in each population, and recording it as
150 a percentage of the day's population (Lee et al., 2006). Worms were considered dead
151 when they no longer responded in any way to the stimulus of contact with the worm pick,
152 and were removed from the plates (Lee et al., 2006). Worms were censored if they crawled
153 off the plate or died from vulvul bursting. Data from the lifespan assay were analyzed using
154 Kaplan-Meier Survival curves with the statistical significance determined by log-rank
155 analysis in Minitab Statistical Software. Differences were considered statistically
156 significant at $p < 0.05$.

157

158 *Motility Assays*

159 The effect of DR on motility of *C. elegans* was determined by a motility assay (Herndon *et*
160 *al.*, 2002). Worms were treated as per the lifespan assay described above and started on
161 day 1 of adulthood (L4 stage, young adult), immediately after transfer of the synchronized
162 adult worms to their respective treatment plates. For each motility assay, 4 plates with 15
163 adult worms each were used per treatment, giving a total of 60 individuals per treatment.
164 Motility was recorded every day for the different treatment groups until the end of the
165 population's lifespan, typically 3-4 weeks. Briefly, motility was assessed daily by
166 subjecting the worms to gentle stroking with a worm pick and their response to the stimulus
167 was grouped into one of three classes and then the percentage of the total living
168 population on the observation day in each class was recorded. The classes were defined
169 as follows: Class 1 shows continuous smooth movement and fast movement when
170 stimulated, Class 2 individuals display slow halting movement and smooth movement
171 when stimulated whereas Class 3 shows small movement of head or tail and very slow

172 movement when stimulated (Golden et al., 2008). Non-linear regression analysis (Prism
173 software) was used to determine the average number of days for 50% of the initial
174 population to move from motility class 1 to class 2 (parameter C_{1-2}), and from class II to
175 class III (parameter C_{2-3}). The average time spend in class II (parameter ΔC_2) is defined
176 as the difference between parameters $C_{2-3} - C_{1-2}$. Statistical significance of motility
177 parameters was determined using One-way ANOVA with Fisher's LSD post hoc test
178 (GraphPad Prism 9).

179

180 *Fluorescence microscopy*

181 Fluorescence intensity images of *C. elegans* were measured by taking a random sample
182 of 5 specimens from each DR population. Measurements started on day 1 of adulthood
183 (L4 stage, young adult), immediately after transfer of the synchronised adult worms to
184 their respective treatment plates. After day 2 of adulthood, fluorescence measurements
185 were done every other day (e.g., day 4, 6, 8, 10, 12, 14, 16....) until the end of the
186 population's lifespan, typically 3-4 weeks. The worms were immobilized on slides with
187 10 μ l of 1:4 ethanol to M9 buffer solution, and whole-body fluorescence images were taken
188 in the presence of an internal standard, In-Speck Green (505/515 nm) calibration beads,
189 using an Olympus IX83 fluorescence microscope. A standard calibration curve was
190 constructed by plotting the average fluorescence of 10 individual beads for each
191 fluorescence concentration (0.1-100%) (Figure S3). Fluorescence images were corrected
192 for background fluorescence (Patterson et al., 1997) and analyzed using ImageJ
193 (Schneider *et al.*, 2012). Statistical analysis of the fluorescence data was performed by
194 using two-way ANOVA with GraphPad Prism (Version 8.0). Fluorescence differences
195 were considered statistically significant at $p < 0.05$. Fluorescence images were also used
196 to determine average body length and width using Image J software.


197

198 **Results**

199 **Mild and medium DR increases lifespan of *C. elegans unc54::GFP***

200 In order to validate our DR approach and use of *unc54::GFP* strain the effect of various
201 dietary restriction regimes on the lifespan of *C. elegans* (*unc54::GFP*), is depicted in
202 Figure 1 and summarized in Table 1. The extension of mean lifespan was most effective
203 under mild DR conditions with an increase of 28% whereas the medium DR conditions
204 resulted in a moderate increase of 18%. In contrast, the severe DR groups showed a
205 reduction of the mean life span by 16% compared to the control. These findings are
206 consistent with previous studies in which exposure of worms to moderate DR had a
207 beneficial impact on lifespan while severe DR resulted in detrimental effects on lifespan
208 (Greer et al., 2007; Greer and Brunet, 2009; Mair and Dillin, 2008; Piper and Partridge,
209 2007). The median life span of the control group reported here for *C. elegans* (*unc-*
210 *54::GFP*) agrees with previous studies that used wildtype (N2) worms (Bolanowski et al.,
211 1981; Croll et al., 1977; De Cuyper and Vanfleteran, 1982; Hosono et al., 1980), validating
212 using the *unc54::GFP* strain.

213



214

215 **Figure 1: Effect of different DR regimes on *C. elegans* lifespan.** Lifespan assays were
216 done at 20°C. Survival plots were drawn by Kaplan-Meier survival assay followed by Log-
217 rank analysis for statistical significance. The figure shows the result of one experiment
218 and is representative of two independently completed experiments.

219

220

221 **Table 1. Effect of different DR regimes on the mean lifespan of *C. elegans*.** Shown are
 222 the mean and maximum lifespan and the % change compared with control. Negative
 223 values indicate a significant decrease in mean lifespan. Each diet group was compared to
 224 control by the log rank test to determine statistical significance.

225

Diet	Mean lifespan (days)	% Increase in Mean Lifespan	Maximum lifespan (days)	% Increase in Maximum Lifespan
Control	15.5±0.7		22	
Mild	19.9±0.8 ¹	28.4%	27	22.7%
Medium	18.3±0.8 ²	18.1%	26	18.2%
Severe	13±0.8 ³	-16.1%	20	-9.1%

226

227 ¹Statistically different compared to Control, p < 0.001

228 ²Statistically different compared to Control, p = 0.011


229 ³Statistically different compared to Control, p =0.026

230

231

232 **Mild and medium DR increase health span of *C. elegans***

233 Individuals in each DR group were allocated to one of three distinct motility classes (I, II
 234 and III) and health span in *C. elegans* defined as the period where ≥50% of the worm
 235 population is classified as motility class I (J. H. Hahm et al., 2015). The results of the
 236 motility assay are shown in Figure 2 and Figure S2 and summarised in Table 2. In line
 237 with previous findings (Herndon et al. 2002; and Greer et al., 2007) differences in onset
 238 and progression of motility decline was observed across all groups. During the early
 239 stages of adulthood (day 1-3), 100% of the worm population exhibited spontaneous
 240 smooth movement (Class I) (Figure S2A), but the differences became more pronounced
 241 as the worms aged, as can be seen for instance on day 6, 10 and 14 (Figure 2).



242

243 **Figure 2: Effect of dietary restriction on *C. elegans* motility on day 6, 10 and 14.** Classification of

244 movement according to Herndon et al., 2002. (A) Class I – Continuous smooth movement, fast

245 movement when stimulated. (B) Class II – Slow halting movement, smooth movement when

246 stimulated. (C) Class III – Small movement of head or tail, very slow movement when stimulated.

247

248 **Table 2. Summary of age-related changes in motility.** Average number of days for 50% of initial

249 population to move from motility class 1 to class 2 (parameter C_{1-2}) or from class 2 to class 3

250 (parameter C_{2-3} , based on maximum % in class 2). The difference between the two mid-points,

251 represented by parameter ΔC_2 , is the average time spent in class 2. Averages are based on data

252 from two independent experiments and statistical significance was determined using One-way

253 ANOVA ($p < 0.05$).

254

	C_{1-2}	C_{2-3}	ΔC_2	Mean life
	(days)	(days)	(days)	span(days)
Control	7.3 ± 0.4	11.7 ± 0.7	4.4 ± 1.1	15.5 ± 0.7
Mild	10.0 ± 1.4 ¹	15.4 ± 0.1 ¹	5.4 ± 1.4	19.9 ± 0.8
Medium	9.3 ± 0.8 ¹	15.2 ± 0.9 ¹	5.9 ± 0.1	18.3 ± 0.8
Severe	6.9 ± 0.5	10.7 ± 0.7	3.9 ± 0.3	13 ± 0.8


260

¹($p < 0.05$).

261
262 Non-linear regression analysis of motility data (Figure S2) was used to compare
263 the average number of days for 50% of the initial population to move from motility class 1
264 to class 2 (Table 2, parameter C_{1-2}). This revealed that worms under mild and medium DR
265 spend significantly longer in class I ($C_{1-2} = 10.9$ and 9.3 days respectively) compared to
266 control and severe DR ($C_{1-2} = 7.3$ and 6.9 days respectively). Similar analysis showed that
267 transition from class II to class III was also significantly delayed for worms under mild and
268 medium DR ($C_{2-3} = 15.4$ and 15.2 days respectively) compared to control and severe DR
269 (Table 2, parameter $C_{2-3} = 11.7$ and 10.7 days). The average time spend in class II
270 increased as well for the mild and medium DR groups ($\Delta C_2 = 5.4$ and 5.9 days
271 respectively) compared to the control and severe DR populations ($\Delta C_2 = 4.4$ and 3.9 days)
272 although this increase was statistically not significant (compared to control).

273
274 Health span in *C. elegans* is defined as the period where $\geq 50\%$ of the worm population is
275 classified as motility class I, while gerospan is defined as the period when $\geq 50\%$ of the
276 worm population has lost its class I motility (Bansal *et al.*, 2015). Using the motility data
277 (parameter C_{1-2} , Table 2), the health span period for control and severe DR was just under
278 seven days, whereas for mild and medium DR the healthspan was extended to 8.5 days
279 (Figure 3A). Altogether, these findings show that mild and medium DR-treated worms
280 retained movement capability longer and thus had a longer health span compared to
281 control and severe DR, although the resulting normalized healthspan to gerospan ratios
282 were similar among the various DR groups (Figure 3B). Thus, although the healthspan
283 period is extended for mild/medium DR, for these groups the gerospan period was
284 prolonged as well. This suggests that mild/medium DR not induce prolonged healthspan
285 overall, but rather delay the onset of gerospan.

286



287

288 **Figure 3: Comparison of healthspan and gerospan in control and DR groups.** A) Healthspan was

289 defined as the period when > 50% of the initial nematode population show type-I motility.

290 Gerospan was defined as the period when < 50% of the initial nematode population show < 50%

291 of type-I motility. B) The ratio of healthspan to gerospan was normalized to their maximal lifespan

292 in control and DR worms (J. H. Hahm et al., 2015).

293

294

295 **Age-dependent decline in myosin levels is delayed under mild and medium DR**
 296 **conditions.**

297 To quantify the loss of muscle mass under various DR conditions, we used fluorescence

298 microscopy to visualize the body wall muscles of UNC54-GFP transgenic worms over the

299 entire lifespan of *C. elegans*. The calibration curve of the GFP-standards confirmed

300 linearity ($R^2 = 0.999$) with a limit of detection (LOD) = 4028 (0.17%) and a limit of

301 quantitation (LOQ) = 4621 (0.51%) as shown in Figure S3. Figure 4A shows

302 representative fluorescence images for all four DR groups at different time points (day 4,

303 10, and 14), illustrating fluorescence intensity increased and decreased in an age-related

304 manner (for a full data set of fluorescence intensity over lifespan see Figure S4). Boxplots


305 of fluorescence intensity start to show significant differences in fluorescence for mild DR

306 and medium DR groups compared to control from day 10 onwards (Figure 4B). The

307 fluorescence data in this study do not address heterogeneity in the fluorescence of

308 individual worms. as the individuals used for fluorescence measurements were randomly

309 selected, based on age and diet, and their motility was not considered. Therefore, at
 310 certain timepoints, one could have individuals from different motility classes and hence a
 311 wider data spread in fluorescence intensity (Figure 4B).



312

313 **Figure 4: Visualisation of muscle density over *C. elegans* lifespan using fluorescently labelled**

314 **myosin (UNC54-GFP).** (A) Representative fluorescence microscopy images of *C. elegans* grown

315 under various DR conditions (mild, medium, severe) compared with control (no restriction) at day

316 4, 10, and 14. (B) Myosin UNC-54 density of body-wall muscle at different time points for various

317 DR conditions (mild, medium, severe) compared to control (no restriction). * Indicates significant

318 differences between the control and DR groups (* $P < 0.05$) using 2-way ANOVA.

319 The increase in fluorescence seen during the first eight days of adulthood is indicative of
320 the rate of muscle growth. The medium DR group on average shows the largest increase
321 in myosin density, followed by mild DR and control, whereas severe DR consistently
322 showed the lowest myosin density increase although statistically not significantly different
323 (Figure 5A). A decrease in fluorescence is seen after day 8 (Figure 5B) with the amount
324 of GFP-labelled myosin (UNC54-GFP) reducing for all groups. Single exponential fits of
325 the average fluorescence intensity show that mild and medium DR groups lost 50% of
326 their maximum UNC54-GFP myosin at 15.3 days and 14.8 days respectively ($t_{1/2}$ in Table
327 3), compared to control and severe DR groups which lost 50% of peak UNC54-GFP
328 myosin at 12 days and 13.1 days, respectively. The rate at which UNC54-GFP levels
329 decrease, represented by the rate of fluorescence loss (k_F in Table 3), is slower for mild
330 and medium DR compared to control and severe DR, suggesting that the onset and rate
331 of sarcopenia is delayed in worms under mild and medium DR, compared to the control
332 and severe DR groups. No significant differences in average body length and width were
333 found for the mild DR and medium DR groups, compared to control, whereas the severe
334 DR group did show lower average body length and width compared to control (Figure 6).
335

336 **Table 3. Summary of age-related changes in fluorescence and expression of**
337 **myosin UNC54-GFP.**

	Fluorescence increase ¹ (10^5 day^{-1})	Fluorescence loss ² k_F (day^{-1})	$t_{1/2}$ ³ (days)	$T_{0.5}$ UNC54-GFP ⁴ (day)
Control	3.4±0.6	0.14±0.03	5.0	13.0
Mild	3.5±0.3	0.052±0.005	13.4	21.4
Medium	4.9±0.3	0.066±0.005	10.6	18.6
Severe	2.6±0.4	0.14±0.03	5.0	13.0


338 ¹Measured from day 1- 8.

339 ²Determined from day 8 (maximum fluorescence) until day 24.

340 ³Determined using $\ln(2)/k_F$

341 ⁴Age at which 50% of maximum UNC-54-GFP myosin is lost.

342



343

344 **Figure 5: Expression of myosin UNC54-GFP as a function of age.** Average

345 fluorescence intensity with standard deviation is shown (n=5). (A) Average fluorescence

346 increases during day 1-8 for the various DR groups. Linear regression resulted in values

347 for mild and medium DR with slope = $3.5 \pm 0.3 \times 10^5$ and $4.9 \pm 0.3 \times 10^5$ respectively

348 (corresponding R^2 -values of 0.97 and 0.99). Control and severe DR groups yielded

349 slopes of $3.4 \pm 0.6 \times 10^5$ and $2.6 \pm 0.4 \times 10^5$ respectively (R^2 -values of 0.91 and 0.93). (B)

350 Average fluorescence decreases from day 8 towards end of lifespan for control, mild

351 DR, medium DR and severe DR. Single exponential fits were used to calculate $t_{1/2}$


352 values of 13.0 days (control), 18.4 days (mild), 15.6 days (medium) and 12.9 days

353 (severe). a rate of fluorescence loss k_F of 0.14 days^{-1} (control), 0.052 days^{-1} (mild), 0.066

354 days^{-1} (medium) and 0.14 days^{-1} (severe). (R^2 -values = 0.86 (control), 0.95 (mild), 0.97

355 (medium) and 0.89 (severe).

356



358

359 **Fig. 6. Body length and body width of *C. elegans* (*unc-54::gfp*) exposed to various**360 **dietary treatments. (A) Average body length of *unc-54::gfp* worms exposed to various**361 **DR regimes. (B) Average body width of *unc-54::gfp* worms exposed to various DR**362 **regimes. Statistical analysis was one-way ANOVA, followed by Dunnett's post hoc**363 **analysis (N=27 control, N= 33 mild DR, N=33 medium DR, N=28 severe DR). (* p< 0.05;**364 **** p< 0.005).**

365

366


367 **Discussion**368 In order to quantify sarcopenia rates, this work used the sDR method and a transgenic *C.*369 *elegans* strain (*unc-54::GFP*), to determine myosin density in *C. elegans* body wall muscle370 during its complete life span. Based on the average rate of fluorescence decrease (k_F),

371 loss of UNC54 myosin is about two-fold slower for the mild and medium sDR groups

372 compared to control and severe sDR. The timepoint by which the average fluorescence

373 intensity is 50% of the maximum fluorescence ($t_{1/2}$ value) and the corresponding rate of374 fluorescence loss (k_F) correlate well with the time point in the motility assay when moving375 from class I to class II (C_{1-2}), which agrees with previous studies that reported a good

376 correlation between maximum velocity of *C. elegans* and health span (J.-H. Hahm et al.,
 377 2015). Thus, the average rate of UNC-54 myosin loss, representing sarcopenia rates and
 378 reported here for the first time, is a good predictor of health span (C_{1-2}) in *C. elegans*, but
 379 not of lifespan (Figure 7A/B). The timepoint in the motility assay when moving from class
 380 II to class III (C_{2-3}) is a better predictor of lifespan (Figure 7C).
 381



382
 383 **Figure 7: Rate of myosin loss (k_F) correlates with healthspan.** (A) Correlation of rate of myosin
 384 loss (k_F) with mean lifespan (B) Correlation of rate of myosin loss (k_F) with mean healthspan,
 385 from motility parameter C_{1-2} (C) Correlation of motility parameter C_{2-3} and mean lifespan.

386
 387 Protein levels vary over time due to changes in protein synthesis, protein degradation or
 388 both (Ross et al., 2021). The change in protein abundance over time ($d[P]/dt$) is defined
 389 by rate of protein synthesis (k_{syn}) and protein degradation (k_{deg}) according to:

390
 391

$$d[P]/dt = k_{syn} - k_{deg}[P]$$

392
 393 The overall increase in UNC-54 abundance, seen during the first week of adulthood for all
 394 groups, is attributed to UNC-54 synthesis (k_{syn}). The rate of protein degradation (k_{deg}) is

395 presumed zero during the first week of adulthood as UNC-54 protein has been reported
396 to be extremely stable with very slow turnover (Dhondt et al., 2016). The overall
397 fluorescence decrease, seen during the second week of adulthood (Figure 5B), represents
398 overall UNC-54 degradation (first-order process) which follows an exponential decay with
399 degradation rate constant k_{deg} . Reduced myosin UNC-54-GFP degradation rates are
400 found for the mild-DR and medium DR treatment groups compared to control -DR. As
401 there is no significant difference in body length/width between the mild-DR and medium-
402 DR groups, compared to control-DR, this excludes the possibility that changes in myosin
403 UNC-54-GFP levels are caused by the worms being different in size. Protein turnover
404 studies in *C. elegans*, using pulse-labelling methods, reported minimal turnover of proteins
405 of the muscle contractile apparatus. For myosin isoform UNC-54, turnover rates with an
406 average half-life of 298 hr (=12.4 days) have been reported (Dhondt et al., 2016), which
407 is very similar to the $t_{1/2}$ value found here for UNC-54-GFP using fluorescence (control $t_{1/2}$
408 = 13.0 days). Considering the extremely slow turnover of muscle proteins (Dhondt et al.,
409 2016), the $t_{1/2}$ values measured here for UNC-54-GFP abundance, represent UNC-54
410 protein turnover. Therefore, we predict, based on the $t_{1/2}$ values measured here, that
411 exposure to mild and medium DR results in reduced UNC-54 degradation compared to
412 control.

413

414 Our results align with previous studies that report a decrease in myosin UNC-54 levels in
415 ageing *C. elegans*. Under ad libitum conditions, *unc-54* mRNA expression was found to
416 be downregulated for *C. elegans* (Matheny et al., 2022); (Mergoud dit Lamarche et al.,
417 2018) (Adamla and Ignatova, 2015) with an overall decline in UNC-54 protein levels seen
418 from day 8 of adulthood (Matheny et al., 2022). Under DR conditions there is conflicting
419 data, as some studies report upregulation of *unc-54* mRNA (Rollins et al., 2019) whereas
420 another study reports *unc-54* mRNA levels unchanged as a result of DR (Depuydt et al.,
421 2013). Changes in mRNA levels are not always a good predictor for changes in protein
422 abundance (Kamkina et al., 2016) and therefore direct measurements of UNC-54 protein

423 levels could be more informative. It was reported previously that muscle preservation in
424 *C. elegans* exposed to DR, is not due to increased mRNA expression, and therefore other
425 mechanisms, like selective inhibition of muscle protein degradation, must be involved in
426 maintaining increased UNC-54 levels under DR conditions compared to control (Depuydt
427 et al., 2013). Our results align with those findings, although with the caveat that the DR
428 methods between the two studies differ (solid DR versus liquid DR). As different DR
429 methods can induce different signaling pathways (Greer and Brunet, 2009) future studies
430 using liquid DR, are needed to address this in more detail.

431

432 Using this UNC-54-GFP method allows quantification of subtle changes in sarcopenia
433 rates in *C. elegans* which can be used as a starting point to develop a screening method
434 to determine sarcopenia rates in response to various interventions. Although the results here
435 demonstrate the potential of this GFP-based technique in *C. elegans*, further studies are needed to
436 optimize the methodology, considering the heterogeneity in the individual worms, and address
437 the autofluorescence, caused by lipofuscin that accumulates in the intestine with age
438 (Pincus et al., 2016). Although the present study was able to reduce the autofluorescence
439 effect by selecting the body wall muscle region, and not the intestine, a triple band GFP
440 filter is needed to validate this in more detail (Teuscher & Ewald, 2018).

441

442 Numerous studies have demonstrated that, in *C. elegans*, the life-extending effect of DR
443 is controlled by a number of overlapping and independent signaling pathways (Chamoli et
444 al., 2014; Cypser et al., 2013; Greer and Brunet, 2009; Walker et al., 2005). In addition,
445 many studies have shown a decrease in skeletal muscle metabolism with aging, mostly
446 due to a decrease in mitochondria activity (Figueiredo et al., 2009; Pugh et al., 2013; Short
447 et al., 2005; Yamada et al., 2013). Conversely, there is growing evidence indicating that
448 metabolic reprogramming that occurs in response to DR, may underlie the beneficial
449 effects of DR (Anderson and Weindruch, 2010; Barger et al., 2015; Feng et al., 2016).
450 Given this plethora of signalling pathways, it is likely that the DR employed in this study

451 could act on several distinct pathways to extend lifespan and motility in *C. elegans*.
452 Moreover, the considerable difference in lifespan and motility between the different DR
453 regimens, supports the idea that DR affects lifespan and motility through distinct
454 pathways. More recently, Rhoads et al., demonstrated that the preservation of muscle
455 mass and physical function, frequently seen with dietary-restricted rhesus monkeys are
456 linked with metabolic pathways (Rhoads et al., 2020).

457

458 In conclusion, to quantify sarcopenia rates in *C. elegans* we have measured myosin UNC-
459 54-GFP density over its entire lifespan, using an internal GFP-standard, As UNC-54
460 proteins demonstrate extreme slow turnover, this method allowed us to determine UNC-
461 54 synthesis and degradation rates at various DR treatments. Our results showed reduced
462 UNC-54 degradation rates for moderate DR compared to control, which correlated well
463 with improved motility parameters and lifespan. This suggests that moderate DR allow *C.*
464 *elegans* to maintain UNC-54 levels and protein homeostasis for longer periods and
465 thereby delaying the onset of sarcopenia.

466

467

468

469 **Competing interest**

470 The authors declare no competing interests.

471 **Author contributions**

472 MB and SH provided study design. All authors acquired, analysed, or interpreted data.

473 ST and MB drafted the manuscript with the help of all co-authors. MB supervised the

474 study.

475 **Acknowledgements**

476 We thank Dr András Málnási-Csizmadi (Eötvös Loránd University, Budapest, Hungary)

477 for generously providing the *C.elegans* strain with GFP-labelled myosin (*unc54::gfp*).

478 This work was supported by the QR CCCU research fund to MJB, a CCCU PhD

479 scholarship to ST and a summer internship grant (RED) to AS.

480

481 **References (updated)**

- 482 Adamlá, F., Ignatova, Z., 2015. Somatic expression of *unc-54* and *vha-6* mRNAs
483 declines but not pan-neuronal *rgef-1* and *unc-119* expression in aging *Caenorhabditis*
484 *elegans*. *Sci Rep* 5, 10692. <https://doi.org/10.1038/srep10692>
- 485 Anderson, R.M., Weindruch, R., 2010. Metabolic reprogramming, caloric restriction and
486 aging. *Trends in Endocrinology and Metabolism*.
487 <https://doi.org/10.1016/j.tem.2009.11.005>
- 488 Bansal, A., Zhu, L.J., Yen, K., Tissenbaum, H.A., 2015. Uncoupling lifespan and
489 healthspan in *Caenorhabditis elegans* longevity mutants . *Proceedings of the National*
490 *Academy of Sciences*. <https://doi.org/10.1073/pnas.1412192112>
- 491 Barger, J.L., Anderson, R.M., Newton, M.A., Da Silva, C., Vann, J.A., Pugh, T.D.,
492 Someya, S., Prolla, T.A., Weindruch, R., 2015. A conserved transcriptional signature of
493 delayed Aging and reduced disease vulnerability is partially mediated by SIRT3. *PLoS*
494 *ONE*. <https://doi.org/10.1371/journal.pone.0120738>
- 495 Bolanowski, M.A., Russell, R.L., Jacobson, L.A., 1981. Quantitative measures of aging
496 in the nematode *Caenorhabditis elegans*. I. Population and longitudinal studies of two
497 behavioral parameters. *Mechanisms of Ageing and Development*.
498 [https://doi.org/10.1016/0047-6374\(81\)90136-6](https://doi.org/10.1016/0047-6374(81)90136-6)
- 499 Chamoli, M., Singh, A., Malik, Y., Mukhopadhyay, A., 2014. A novel kinase regulates
500 dietary restriction-mediated longevity in *Caenorhabditis elegans*. *Aging Cell*.
501 <https://doi.org/10.1111/accel.12218>
- 502 Ching, T.T., Hsu, A.L., 2011. Solid plate-based dietary restriction in *Caenorhabditis*
503 *elegans*. *Journal of visualized experiments : JoVE*. <https://doi.org/10.3791/2701>
- 504 Christian, C.J., Benian, G.M., 2020. Animal models of sarcopenia. *Aging Cell* 19.
505 <https://doi.org/10.1111/accel.13223>
- 506 Croll, N.A., Smith, J.M., Zuckerman, B.M., 1977. The aging process of the nematode
507 *caenorhabditis elegans* in bacterial and axenic culture. *Experimental Aging Research*.
508 <https://doi.org/10.1080/03610737708257101>
- 509 Cruz-Jentoft, A.J., Sayer, A.A., 2019. Sarcopenia. *The Lancet* 393, 2636–2646.
510 [https://doi.org/10.1016/S0140-6736\(19\)31138-9](https://doi.org/10.1016/S0140-6736(19)31138-9)
- 511 Cypser, J.R., Kitzenberg, D., Park, S.K., 2013. Dietary restriction in *C. elegans*: Recent
512 advances. *Experimental Gerontology*. <https://doi.org/10.1016/j.exger.2013.02.018>
- 513 Dao, T., Green, A.E., Kim, Y.A., Bae, S.J., Ha, K.T., Gariani, K., Lee, M.R., Menzies,
514 K.J., Ryu, D., 2020. Sarcopenia and muscle aging: A brief overview. *Endocrinology and*
515 *Metabolism*. <https://doi.org/10.3803/ENM.2020.405>
- 516 De Cuyper, C., Vanfleteran, J.R., 1982. Nutritional alteration of life span in the nematode
517 *Caenorhabditis elegans*. *AGE*. <https://doi.org/10.1007/BF02431722>
- 518 Depuydt, G., Xie, F., Petyuk, V.A., Shanmugam, N., Smolders, A., Dhondt, I., Brewer,
519 H.M., Camp, D.G., Smith, R.D., Braeckman, B.P., 2013. Reduced Insulin/Insulin-like
520 Growth Factor-1 Signaling and Dietary Restriction Inhibit Translation but Preserve

- 521 Muscle Mass in *Caenorhabditis elegans*. *Molecular & Cellular Proteomics* 12, 3624–
522 3639. <https://doi.org/10.1074/mcp.M113.027383>
- 523 Dhondt, I., Petyuk, V.A., Cai, H., Vandemeulebroucke, L., Vierstraete, A., Smith, R.D.,
524 Depuydt, G., Braeckman, B.P., 2016. FOXO/DAF-16 Activation Slows Down Turnover
525 of the Majority of Proteins in *C. elegans*. *Cell Reports* 16, 3028–3040.
526 <https://doi.org/10.1016/j.celrep.2016.07.088>
- 527 Dhondt, I., Verschuuren, C., Zečić, A., Loier, T., Braeckman, B.P., De Vos, W.H., 2021.
528 Prediction of biological age by morphological staging of sarcopenia in *Caenorhabditis*
529 *elegans*. *Disease Models & Mechanisms* 14, dmm049169.
530 <https://doi.org/10.1242/dmm.049169>
- 531 Domingues-Faria, C., Vasson, M.P., Goncalves-Mendes, N., Boirie, Y., Walrand, S.,
532 2016. Skeletal muscle regeneration and impact of aging and nutrition. *Ageing Research*
533 *Reviews*. <https://doi.org/10.1016/j.arr.2015.12.004>
- 534 Feng, Z., Hanson, R.W., Berger, N.A., Trubitsyn, A., 2016. Reprogramming of energy
535 metabolism as a driver of aging. *Oncotarget*. <https://doi.org/10.18632/oncotarget.7645>
- 536 Figueiredo, P.A., Powers, S.K., Ferreira, R.M., Appell, H.J., Duarte, J.A., 2009. Aging
537 impairs skeletal muscle mitochondrial bioenergetic function. *Journals of Gerontology -*
538 *Series A Biological Sciences and Medical Sciences*.
539 <https://doi.org/10.1093/gerona/gln048>
- 540 Golden, T.R., Hubbard, A., Dando, C., Herren, M.A., Melov, S., 2008. Age-related
541 behaviors have distinct transcriptional profiles in *Caenorhabditis.elegans*. *Aging Cell*.
542 <https://doi.org/10.1111/j.1474-9726.2008.00433.x>
- 543 Greer, E.L., Brunet, A., 2009. Different dietary restriction regimens extend lifespan by
544 both independent and overlapping genetic pathways in *C. elegans*. *Aging Cell*.
545 <https://doi.org/10.1111/j.1474-9726.2009.00459.x>
- 546 Greer, E.L., Dowlathshahi, D., Banko, M.R., Villen, J., Hoang, K., Blanchard, D., Gygi,
547 S.P., Brunet, A., 2007. An AMPK-FOXO Pathway Mediates Longevity Induced by a
548 Novel Method of Dietary Restriction in *C. elegans*. *Current Biology*.
549 <https://doi.org/10.1016/j.cub.2007.08.047>
- 550 Hahm, J.-H., Kim, S., DiLoreto, R., Shi, C., Lee, S.-J.V., Murphy, C.T., Nam, H.G.,
551 2015. *C. elegans* maximum velocity correlates with healthspan and is maintained in
552 worms with an insulin receptor mutation. *Nat Commun* 6, 8919.
553 <https://doi.org/10.1038/ncomms9919>
- 554 Hahm, J.H., Kim, S., Diloreto, R., Shi, C., Lee, S.J. V., Murphy, C.T., Nam, H.G., 2015.
555 *C. elegans* maximum velocity correlates with healthspan and is maintained in worms
556 with an insulin receptor mutation. *Nature Communications*.
557 <https://doi.org/10.1038/ncomms9919>
- 558 Han, A., Bokshan, S., Marcaccio, S., DePasse, J., Daniels, A., 2018. Diagnostic Criteria
559 and Clinical Outcomes in Sarcopenia Research: A Literature Review. *Journal of Clinical*
560 *Medicine*. <https://doi.org/10.3390/jcm7040070>

- 561 Herndon, L.A., Schmeissner, P.J., Dudaronek, J.M., Brown, P.A., Listner, K.M., Sakano,
562 Y., Paupard, M.C., Hall, D.H., Driscoll, M., 2002. Stochastic and genetic factors
563 influence tissue-specific decline in ageing *C. elegans*. *Nature* 419, 808–814.
564 <https://doi.org/10.1038/nature01135>
- 565 Hosono, R., Sato, Y., Aizawa, S.I., Mitsui, Y., 1980. Age-dependent changes in mobility
566 and separation of the nematode *Caenorhabditis elegans*. *Experimental Gerontology*.
567 [https://doi.org/10.1016/0531-5565\(80\)90032-7](https://doi.org/10.1016/0531-5565(80)90032-7)
- 568 Hwangbo, D.S., Lee, H.Y., Abozaid, L.S., Min, K.J., 2020. Mechanisms of lifespan
569 regulation by calorie restriction and intermittent fasting in model organisms. *Nutrients*.
570 <https://doi.org/10.3390/nu12041194>
- 571 Ibáñez-Ventoso, C., Herrera, C., Chen, E., Motto, D., Driscoll, M., 2016. Automated
572 analysis of *C. Elegans* swim behavior using CeleST software. *Journal of Visualized*
573 *Experiments*. <https://doi.org/10.3791/54359>
- 574 Kamkina, P., Snoek, L.B., Grossmann, J., Volkers, R.J.M., Sterken, M.G., Daube, M.,
575 Roschitzki, B., Fortes, C., Schlapbach, R., Roth, A., von Mering, C., Hengartner, M.O.,
576 Schimpf, S.P., Kammenga, J.E., 2016. Natural Genetic Variation Differentially Affects
577 the Proteome and Transcriptome in *Caenorhabditis elegans**. *Molecular & Cellular*
578 *Proteomics* 15, 1670–1680. <https://doi.org/10.1074/mcp.M115.052548>
- 579 Kim, Y.J., Moon, S., Yu, J.M., Chung, H.S., 2022. Implication of diet and exercise on the
580 management of age-related sarcopenic obesity in Asians. *Geriatrics & Gerontology*
581 *International* 22, 695–704. <https://doi.org/10.1111/ggi.14442>
- 582 Kwak, J.Y., Kwon, K.-S., 2019. Pharmacological Interventions for Treatment of
583 Sarcopenia: Current Status of Drug Development for Sarcopenia. *Ann Geriatr Med Res*
584 23, 98–104. <https://doi.org/10.4235/agmr.19.0028>
- 585 Lee, G.D., Wilson, M.A., Zhu, M., Wolkow, C.A., De Cabo, R., Ingram, D.K., Zou, S.,
586 2006. Dietary deprivation extends lifespan in *Caenorhabditis elegans*. *Aging Cell*.
587 <https://doi.org/10.1111/j.1474-9726.2006.00241.x>
- 588 Mair, W., Dillin, A., 2008. Aging and survival: The genetics of life span extension by
589 dietary restriction. *Annual Review of Biochemistry*.
590 <https://doi.org/10.1146/annurev.biochem.77.061206.171059>
- 591 Matheny, C.J., Qadota, H., Kimelman, M., Bailey, A.O., Oberhauser, A.F., Benian,
592 G.M., 2022. UNC-45 has a crucial role in maintaining muscle sarcomeres during aging in
593 *Caenorhabditis elegans*. *bioRxiv* 2022.06.04.494828.
594 <https://doi.org/10.1101/2022.06.04.494828>
- 595 McKiernan, S.H., Bua, E., McGorray, J., Aiken, J., 2004. Early-onset calorie restriction
596 conserves fiber number in aging rat skeletal muscle. *The FASEB journal : official*
597 *publication of the Federation of American Societies for Experimental Biology*.
- 598 Mergoud dit Lamarche, A., Molin, L., Pierson, L., Mariol, M.-C., Bessereau, J.-L.,
599 Gieseler, K., Solari, F., 2018. UNC-120/SRF independently controls muscle aging and
600 lifespan in *Caenorhabditis elegans*. *Aging Cell* 17, e12713.
601 <https://doi.org/10.1111/acel.12713>

602 Park, H.-E.H., Jung, Y., Lee, S.-J. V., 2017. Survival assays using *Caenorhabditis*
603 *elegans*. *Molecules and Cells*. <https://doi.org/10.14348/molcells.2017.0017>

604 Patterson, G.H., Knobel, S.M., Sharif, W.D., Kain, S.R., Piston, D.W., 1997. Use of the
605 green fluorescent protein and its mutants in quantitative fluorescence microscopy.
606 *Biophysical Journal*. [https://doi.org/10.1016/S0006-3495\(97\)78307-3](https://doi.org/10.1016/S0006-3495(97)78307-3)

607 Phu, S., Boersma, D., Duque, G., 2015. Exercise and Sarcopenia. *Journal of Clinical*
608 *Densitometry* 18, 488–492. <https://doi.org/10.1016/j.jocd.2015.04.011>

609 Piper, M.D.W., Partridge, L., 2007. Dietary restriction in *Drosophila*: Delayed aging or
610 experimental artefact? *PLoS Genetics*. <https://doi.org/10.1371/journal.pgen.0030057>

611 Pugh, T.D., Conklin, M.W., Evans, T.D., Polewski, M.A., Barbian, H.J., Pass, R.,
612 Anderson, B.D., Colman, R.J., Eliceiri, K.W., Keely, P.J., Weindruch, R., Beasley, T.M.,
613 Anderson, R.M., 2013. A shift in energy metabolism anticipates the onset of sarcopenia
614 in rhesus monkeys. *Aging Cell*. <https://doi.org/10.1111/accel.12091>

615 Rhoads, T.W., Clark, J.P., Gustafson, G.E., Miller, K.N., Conklin, M.W., DeMuth, T.M.,
616 Berres, M.E., Eliceiri, K.W., Vaughan, L.K., Lary, C.W., Beasley, T.M., Colman, R.J.,
617 Anderson, R.M., 2020. Molecular and Functional Networks Linked to Sarcopenia
618 Prevention by Caloric Restriction in Rhesus Monkeys. *Cell Systems*.
619 <https://doi.org/10.1016/j.cels.2019.12.002>

620 Rollins, J.A., Shaffer, D., Snow, S.S., Kapahi, P., Rogers, A.N., 2019. Dietary restriction
621 induces posttranscriptional regulation of longevity genes. *Life Sci. Alliance* 2,
622 e201800281. <https://doi.org/10.26508/lsa.201800281>

623 Ross, A.B., Langer, J.D., Jovanovic, M., 2021. Proteome Turnover in the Spotlight:
624 Approaches, Applications, and Perspectives. *Molecular & Cellular Proteomics* 20,
625 100016. <https://doi.org/10.1074/mcp.R120.002190>

626 Short, K.R., Bigelow, M.L., Kahl, J., Singh, R., Coenen-Schimke, J., Raghavakaimal, S.,
627 Nair, K.S., 2005. Decline in skeletal muscle mitochondrial function with aging in
628 humans. *Proceedings of the National Academy of Sciences of the United States of*
629 *America*. <https://doi.org/10.1073/pnas.0501559102>

630 Son, H.G., Altintas, O., Kim, E.J.E., Kwon, S., Lee, S.V., 2019. Age-dependent changes
631 and biomarkers of aging in *Caenorhabditis elegans*. *Aging Cell* 18.
632 <https://doi.org/10.1111/accel.12853>

633 Stastna, J.J., Snoek, L.B., Kammenga, J.E., Harvey, S.C., 2015. Genotype-dependent
634 lifespan effects in peptone deprived *Caenorhabditis elegans*. *Scientific Reports*.
635 <https://doi.org/10.1038/srep16259>

636 Stiernagle, T., 2006. Maintenance of *C. elegans*. *WormBook*.
637 <https://doi.org/10.1895/wormbook.1.101.1>

638 Várkuti, B.H., Yang, Z., Kintszes, B., Erdélyi, P., Bárdos-Nagy, I., Kovács, A.L., Hári, P.,
639 Kellermayer, M., Vellai, T., Málnási-Csizmadia, A., 2012. A novel actin binding site of
640 myosin required for effective muscle contraction. *Nature Structural and Molecular*
641 *Biology*. <https://doi.org/10.1038/nsmb.2216>

- 642 Walker, G., Houthoofd, K., Vanfleteren, J.R., Gems, D., 2005. Dietary restriction in *C.*
643 *elegans*: From rate-of-living effects to nutrient sensing pathways. *Mechanisms of Ageing*
644 *and Development*. <https://doi.org/10.1016/j.mad.2005.03.014>
- 645 Wiedmer, P., Jung, T., Castro, J.P., Pomatto, L.C.D., Sun, P.Y., Davies, K.J.A., Grune,
646 T., 2021. Sarcopenia – Molecular mechanisms and open questions. *Ageing Research*
647 *Reviews* 65, 101200. <https://doi.org/10.1016/j.arr.2020.101200>
- 648 Xie, W. qing, Xiao, W. feng, Tang, K., Hu, P. wu, Li, Y. sheng, Duan, Y., Lv, S., 2020.
649 Caloric restriction: implications for sarcopenia and potential mechanisms. *Aging*.
650 <https://doi.org/10.18632/aging.103987>
- 651 Yamada, Y., Colman, R.J., Kemnitz, J.W., Baum, S.T., Anderson, R.M., Weindruch, R.,
652 Schoeller, D.A., 2013. Long-term calorie restriction decreases metabolic cost of
653 movement and prevents decrease of physical activity during aging in rhesus monkeys.
654 *Experimental Gerontology*. <https://doi.org/10.1016/j.exger.2013.08.002>
- 655
- 656
- 657

658 **Supplementary Material:**

659

660 **Table S1: Effect of different DR regimes on the mean lifespan of *C. elegans*.** The

661 table shows mean lifespan and % increase in mean lifespan for each DR group as

662 determined from two independent experiments. Negative values indicate a significant

663 decrease in mean lifespan. Statistical significance in mean lifespan compared to controls

664 was calculated using the Log-rank test (Graphpad Prism 9). In bold, series shown in the

665 survival plot of Figure 1.

Diet	Replicate 1*			Replicate 2*			Mean Lifespan ¹	% Increase in Mean Lifespan ²
	Mean lifespan (days)	% Increase in Mean Lifespan	DR vs Control (p-value)	Mean lifespan (days)	% Increase in Mean Lifespan	DR vs Control (p-value)		
Control	12.3			15.5			13.9±1.6	
Mild	17.3	40.7	0.0052	18.2	17.4	<0.0001	17.8±0.5	29.1
Medium	16.7	35.9	0.0365	17.6	13.6	0.0081	17.2±0.5	24.8
Severe	11.5	-6.8	0.0249	12.9	-16.8	0.0261	12.2±0.7	-11.8

666 *Each replicate used 240 worms, with 60 worms per diet group (4x15 individuals).

667

668

669 **Table S2: Summary of age-related changes in motility under DR from two**
670 **independent experiments.** The table shows the average number of days for 50% of the
671 initial population to move from motility class I to class II, represented by C_{1-2} , and
672 average number of days for 50% of the class II population (based on maximum % in
673 class II) to move to class III (represented by C_{2-3}). The difference between the two mid-
674 points (C_{1-2} and C_{2-3}) was used to calculate the average time spent in class 2, represented
675 by parameter ΔC_2 . Statistical significance compared to control was calculated using the
676 One-way ANOVA, Graphpad Prism 9.

	Replicate 1*			Replicate 2*		
Diet	C_{1-2} (days)	C_{2-3} (days)	ΔC_2 (days)	C_{1-2} (days)	C_{2-3} (days)	ΔC_2 (days)
Control	7.7	11.0	3.3	6.9	12.4	5.5
Mild	11.3	15.3	4.0	8.6	15.4	6.8
Medium	10.1	16.0	5.9	8.5	14.3	5.8
Severe	7.3	11.4	4.1	6.4	10.0	3.6
Averages						
Diet	C_{1-2} (days) ¹	DR vs Control (p-value)	C_{2-3} (days) ²	DR vs Control (p-value)	ΔC_2 (days) ³	DR vs Control (p-value)
Control	7.3±0.4		11.7±0.7		4.4±1.1	
Mild	10.0±1.4	0.023	15.4±0.1	0.030	5.4±1.4	0.453
Medium	9.3±0.8	0.048	15.2±0.9	0.034	5.9±0.1	0.301
Severe	6.9±0.5	0.520	10.7±0.7	0.416	3.9±0.3	0.668

677 *Each replicate used 240 worms, with 60 worms per diet group (4x15 individuals).
678

679 ¹Average motility parameter C_{1-2} was calculated from individual C_{1-2} values.

680 ²Average motility parameter C_{2-3} was calculated from individual C_{2-3} values.

681 ³Average time spent in class 2: average C_{2-3} – average C_{1-2}


682

683

684

685

686



687

688 **Figure S1: Schematic representation of the DR assays using *C. elegans***
 689 **expressing GFP-tagged *unc-54* (*unc54::GFP*).**


690

691

692

693



694



695

696 **Figure S2. Age-related changes in motility of DR worms.** Classification of
697 movement according to Herndon et al., 2002. (A) Class I – Continuous smooth
698 movement, fast movement when stimulated. (B) Class II – Slow halting
699 movement, smooth movement when stimulated. (C) Class III – Small movement
700 of head or tail, very slow movement when stimulated. Data is normalised with
701 maximum number of worms at the start of the assay set at 100%. (A) and (B) are
702 two independent experiments.

703



704

705 **Figure S3: GFP-labelled microbeads were used as an internal fluorescence**

706 **intensity standard.** A) Left panel: Fluorescence microscope image of GFP-

707 labelled microbeads (3%) in M9 buffer. B) Right panel: Calibration curve of

708 microsphere concentration versus average fluorescence intensity shows a good

709 correlation between the different relative microsphere concentrations ($R^2 =$

710 0.9986). All replicates are shown here, indicating the data spread.

711

712 **GFP-calibration curve detailed analysis:**

713 GFP-beads and Image J analysis gave following intensities:

GFP (%)	1	2	3	4	5	6	7	8	9	10
0.3	1624	1624	439	346	405	2352	1033	829	1975	351
1	5580	6263	7034	8064	6932	6139	2757	3103	3273	3037
3	12290	11310	10846	10825	10212	10792	10748	10379	14377	15442
10	19886	19775	22181	24049	23431	25231	27520	22920	23793	23602
30	62655	56385	62166	55692	52422	55846	53999	46417	50542	54140
100	171918	187816	194615	178633	195478	168711	164197	182644	168640	

714

715 After background correction, non-linear regression using Prism gives the following:

716 Best fit model: $Y = Y(\text{intercept}) + \text{slope} * X$

717 Equation found by Prism: $Y = 3736 + 1753 * X$

718 Standard error of slope: 28.01

719 Standard error of intercept: 1200

720 $R^2 = 0.999$ (confirms linearity)

721 **From standard error to standard deviation:** $SD = SE * \sqrt{(n)} (n=10);$

722 $SD \text{ slope} = 28.01 * \sqrt{10} = 88.58$

723 $SD \text{ intercept} = 1200 * \sqrt{10} = 3794$

724 **Limit of detection (LOD) defined as:**

725 $Y_{LOD} = 3.3 * SD (\text{slope}) + \text{intercept} = (3.3 * 88.58) + 3736 = 4028$

726 Corresponding concentration LOD (C_{LOD}):

727 $C_{LOD} = (Y_{LOD} - \text{intercept}) / \text{slope} = (4028 - 3736) / 1753 = 0.17 \%$

728 **Limit of quantitation (LOQ):**

729 $Y_{LOQ} = 10 * SD (\text{slope}) + \text{intercept} = (10 * 88.58) + 3736 = 4621$

730 Corresponding concentration LOQ (CLOQ):

731 $CLOQ = (Y_{LOQ} - \text{intercept}) / \text{slope} = (4621 - 3736) / 1753 = \mathbf{0.51\%}$

732


733 Measured fluorescence intensities < 4621 cannot be accurately quantified and relative
734 GFP concentrations < 0.5% can also not be determined accurately as these are below the
735 LOQ.

736

737 To reduce the effect of autofluorescence, known to increase as *C. elegans* ages, only the
738 body wall muscle area of *C. elegans* was selected for fluorescence analysis, and not the
739 whole worm body.

740

741



742

743

744 **Figure S4: Average fluorescence intensity as a function of age under**
745 **control and various DR conditions, expressing UNC54: GFP.** Fluorescence
746 intensity represents myosin density of body-wall muscle at different time points
747 for various DR conditions (mild, medium, severe) compared to control (no
748 restriction). (Two-way ANOVA, *P < 0.05). Shown are averages from two
749 independent experiments.

750

751

752

753

754

755